Shanghai Jinshan Pharmaceutical Co., Ltd.

Primary objective: In accordance with relevant bioequivalence testing regulations, cyproheptadine hydrochloride tablets (trade name: Periactin, strength: 4mg), manufactured by Alfasigma S.p.A., were selected as the reference formulation. A human bioequivalence study was conducted on the test formulation, cyproheptadine hydrochloride tablets (strength: 4mg), manufactured and supplied by Shanghai Ideal Pharmaceutical Co., Ltd., under fasting and postprandial administration conditions. The study compared the absorption rate and extent of absorption of the drug in the test formulation with those in the reference formulation to determine if the differences were within acceptable ranges, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary objective: To observe the safety of oral administration of the test formulation, cyproheptadine hydrochloride tablets (strength: 4mg), and the reference formulation, cyproheptadine hydrochloride tablets (trade name: Periactin, strength: 4mg), in healthy participants.

Primary Objective To compare the absorption rates and extent of benzbromarone tablets (50 mg) supplied by Shanghai Ideal Pharmaceutical Co., Ltd. with those of benzbromarone tablets (50 mg; trade name: Urinorm®) certified by Toa Ayo Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary Objective To evaluate the safety of benzbromarone tablets (50 mg) supplied by Shanghai Ideal Pharmaceutical Co., Ltd. with those of benzbromarone tablets (50 mg; trade name: Urinorm®) certified by Toa Ayo Co., Ltd. in healthy adults under fasting and postprandial administration conditions.

Primary Objective: In accordance with relevant bioequivalence testing regulations, selegiline hydrochloride tablets (trade name: midopyr®, strength: 5mg), manufactured by Orion Corporation, were selected as the reference formulation. A preliminary human bioequivalence study was conducted on the test formulation selegiline hydrochloride tablets (strength: 5mg), manufactured and supplied by Shanghai Ideal Pharmaceutical Co., Ltd., under fasting administration conditions. The pharmacokinetic behavior of the two formulations in healthy Chinese participants was compared to assess the likelihood of bioequivalence under fasting administration conditions, providing a reference for the design of the formal trial. Secondary Objective: To observe the safety of oral administration of the test formulation selegiline hydrochloride tablets (strength: 5mg) and the reference formulation selegiline hydrochloride tablets (trade name: midopyr®, strength: 5mg) to healthy participants.